Standout Papers
- Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2024)
- Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus (2022)
Immediate Impact
2 from Science/Nature 59 standout
Citing Papers
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
2025 Standout
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
Works of José Luis Górriz being referenced
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
2022 Standout
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| José Luis Górriz | 1390 | 1062 | 656 | 183 | 3.4k | |
| Gozewijn D. Laverman | 1143 | 1181 | 817 | 117 | 2.9k | |
| David J. Leehey | 1453 | 843 | 984 | 108 | 3.3k | |
| Bruno Vogt | 1240 | 800 | 425 | 207 | 3.9k | |
| Enrique Morales | 1769 | 1053 | 670 | 193 | 4.3k | |
| Tadashi Toyama | 933 | 1011 | 349 | 129 | 2.9k | |
| Yoshihiko Kanno | 1425 | 543 | 1155 | 175 | 3.6k | |
| Tzong‐Shinn Chu | 1579 | 724 | 540 | 141 | 3.6k | |
| María José Soler | 1147 | 1351 | 1243 | 194 | 4.6k | |
| W. Gordon Walker | 1560 | 763 | 1015 | 78 | 4.0k | |
| Jamie P. Dwyer | 1051 | 1030 | 659 | 86 | 2.8k |
All Works
Login with ORCID to disown or claim papers
Loading papers...